Hybribio Monkeypox Virus Nucleic Acid Test, SOX1 and PAX1 Methylation Real-time PCR Kit, and SOX1-OT and HIST1H4F Methylation Real-time PCR Kit recently met the compliance requirements of the EU medical device related directives and received the EU CE certification, allowing them to be marketed and sold in EU countries and countries that recognize the EU CE certification.

Rapid Response Helps Global Fight Against Monkeypox Virus

The World Health Organization (WHO) has begun reporting monkeypox cases in European countries since May 16, 2022, and currently there are 131 confirmed and 106 suspected cases of Monkeypox that have been reported in 19 countries. The outbreak of monkeypox in Europe and other countries is unprecedented and it is likely to spread further in the future.

Hybribio Monkeypox Virus Real-time PCR Kit provides a rapid test basis for the diagnosis, treatment and prevention and control of monkeypox virus infection, which helps infected patients in receiving prompt diagnosis.

Monkeypox Virus Real-time PCR Kit

● Quickest detection time is 36 minutes.

● PCR reaction solution is ready-to-use and once aliquoted, the sample can be added to it directly, which cuts the extra operation time of enzyme addition and avoids uneven mixture that leads to system errors.

● High specificity and sensitivity.

● Compatible to various Fluorescent PCR Systems: ABI 7500, QuantStudioTM 5, SLAN 96S, Hybribio Automatic nucleic acid extraction workstation HB-IEX96A, applying to different circumstances.

The deployment of efficient diagnosis and screening, as well as effective preventative methods, is critical in the face of the monkeypox outbreak. Hybribio Monkeypox Virus Real-time PCR Kit are now available for CDC and other research organizations for usage and study purpose.

DNA Methylation Helps in the Early Cancer Detection

Abnormal DNA methylation is associated with the development of many human diseases, including tumors, and epigenetic changes in genes precede histopathological changes. DNA methylation levels will alter in some way during the transformation of normal cells into tumor cells, making it feasible to identify tumor cells by detecting this change.

DNA methylation occurs in pre-cancerous or early stages of cancer, and the methylation of SOX1 and PAX1 genes is linked to the development of cervical cancer and can be utilized as biomarkers for cervical cancer and precancerous lesions. Hybribio SOX1 and PAX1 Methylation Real-time PCR Kit can be applied to triage, prognosis of cervical lesion regression and prognosis monitoring for 14 high-risk HPV positive populations. Hybribio's self-developed automated instruments can be used to extract and convert data, which can significantly minimize manual operation time and enhance testing efficiency. HPV, cervical liquid-based cytology (TCT), and gene methylation tests can be completed in one sampling using Hybribio's product chain in the field of women and children, which has the advantages of precision, efficiency, and speed.

Bladder cancer is one of the most common malignant tumors of the urinary system, with insidious onset and high recurrence rate after surgery. The current gold standard for preoperative diagnosis and postoperative recurrence monitoring is invasive cystoscopy, which not only causes pain to patients, but also may lead to urinary tract injury and infection, etc. Studies have shown that DNA methylation plays a key role in the occurrence and development of bladder cancer and can be used as a biomarker for early diagnosis and prognosis of bladder cancer. Hybribio SOX1-OT and HIST1H4F Methylation Real-time PCR Kit can be used for bladder cancer detection by collecting urine sample, which is highly sensitive, specific, non-invasive and convenient compared with traditional clinical testing methods, and can be used as an effective tool for non-invasive early detection and prognosis monitoring of bladder cancer.

Standardized and effective genetic testing tools and products have become an important commercial necessity in the era of precision medicine. To meet the growing clinical testing needs, Hybribio will continue to expand its product pipelines, promote the transformation and clinical application of advanced scientific and technological achievements, and secure global human health with higher quality, high throughput, and high sensitivity testing products.

Welcome to call for enquiry

Contact: Mr Zheng

Tel: +86-768-2852923 Ext. 8160

Mobile: +86 13929696820